Trafalgar International (GCAN) Interest & Investment Income (2018 - 2025)
Trafalgar International (GCAN) posted Interest & Investment Income of $1313.0 for Q3 2025, up 122.94% on a QoQ basis from -$5723.0 in Q4 2024, and up 122.95% year-over-year from $588.93 in Q3 2024.
Powered by 
Analysis
Trafalgar International (GCAN) Interest & Investment Income (2018 - 2025) Analysis & Trends
Trafalgar International has reported Interest & Investment Income for 4 years, with the latest figure at $1313.0 in Q3 2025.
- On a quarterly basis, Interest & Investment Income rose 122.95% year-over-year to $1313.0 in Q3 2025; TTM through Dec 2025 was -$10132.0, a 34.28% increase from a year earlier, with the FY2025 full-year figure at -$1627.0, up 92.85% from the prior year.
- Interest & Investment Income was $1313.0 for Q3 2025 at Trafalgar International, up from -$5723.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $1313.0 in Q3 2025, with the low at -$5723.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 219.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -679.00 Mn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 89.50 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 35.58 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 38.12 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 31.50 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 1,313.00 |
| Dec 31, 2024 | -5,723.00 |
| Sep 30, 2024 | -5,722.00 |
| Sep 30, 2019 | -3,972.00 |
| Sep 30, 2018 | -14,515.00 |
| Mar 31, 2018 | 5,903.00 |